<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040090</url>
  </required_header>
  <id_info>
    <org_study_id>KAMRAB-003</org_study_id>
    <nct_id>NCT02040090</nct_id>
  </id_info>
  <brief_title>Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects</brief_title>
  <acronym>KAMRAB-003</acronym>
  <official_title>A Prospective, Randomized, Double-Blind, Non Inferiority, Phase II/III Study of the Safety and Efficacy of Simulated Post-Exposure Prophylaxis With Kamada Human Rabies Immune Globulin (KamRAB) and Active Rabies Vaccine in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kamada, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kamada, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in&#xD;
      comparison with Human rabies immune globulin (HRIG) comparator product. 2. To assess whether&#xD;
      KamRAB interferes with the development of self active antibodies when given simultaneously&#xD;
      with active rabies vaccine, as compared to the HRIG comparator product, also given in&#xD;
      conjunction with the active rabies vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-blind, and single period non-inferiority and safety&#xD;
      study conducted at a single study site. Subjects were randomized into the following two&#xD;
      groups:&#xD;
&#xD;
      Group A: KamRAB (20 IU/kg by weight [bw]) intramuscular (IM), rabies vaccine (1.0 mL; ≥2.5&#xD;
      IU/mL) IM Group B: Human rabies immune globulin (HRIG) Comparator product (20 IU/kg bw) IM,&#xD;
      rabies vaccine (1.0 mL; ≥2.5 IU/mL) IM The primary endpoint was a dichotomous (0-1) variable,&#xD;
      defined by reaching an anti-rabies immunoglobulin G (IgG) concentration ≥0.5 IU/mL on Day 14.&#xD;
      The primary hypothesis was that the proportion of KamRAB + vaccine recipients with&#xD;
      anti-rabies concentration ≥0.5 IU/mL on Day 14 would not be less than the corresponding&#xD;
      proportion of HRIG Comparator subjects by as much as 0.1.&#xD;
&#xD;
      The safety and tolerability of the study treatments was assessed based on: vital signs and&#xD;
      physical examination findings, electrocardiogram (ECG), laboratory findings (hematology,&#xD;
      clinical chemistry, and urinalysis) and the occurrence of adverse events (AEs) after drug&#xD;
      administration&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Difference Between KamRAB and HRIG Comparator, in the Proportions of Subjects With Serum Anti-rabies IgG Antibody Concentration ≥ 0.5 IU/mL</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Rabies</condition>
  <arm_group>
    <arm_group_label>KamRAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KamRAB 20 IU/kg body weight via IM injection, once on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDA approved HRIG product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator product: Intramuscular (IM) injection once on Day 0 in the same manner and at the same dosage as KamRAB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active rabies vaccine (US-FDA approved)</intervention_name>
    <description>A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.</description>
    <arm_group_label>FDA approved HRIG product</arm_group_label>
    <arm_group_label>KamRAB</arm_group_label>
    <other_name>RabAvert®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to sign an informed consent.&#xD;
&#xD;
          -  Healthy male or female subjects of 18 - 75 years of age inclusive who have not&#xD;
             previously been immunized against rabies.&#xD;
&#xD;
          -  Ability to comply with completion of a home diary.&#xD;
&#xD;
          -  No previous exposure to Rabies epidemic, Rabies vaccine and/or Rabies Immune globulin.&#xD;
&#xD;
          -  No significant abnormalities in serum hematology, serum chemistry and serum&#xD;
             immunogenic markers (C3, C4 and C50) according to the Principal Investigator's&#xD;
             judgment.&#xD;
&#xD;
          -  No significant abnormalities in urinalysis according to the Principal Investigator's&#xD;
             judgment.&#xD;
&#xD;
          -  No significant abnormalities in ECG per investigator judgment.&#xD;
&#xD;
          -  Non-pregnant, non-lactating female subjects, whose screening pregnancy test is&#xD;
             negative and who are using contraceptive methods deemed reliable by the investigator,&#xD;
             or who are more than 5 years post-menopausal or surgically sterilized.&#xD;
&#xD;
          -  Male subjects must be using at least one effective contraceptive method before study&#xD;
             start and throughout the entire duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or laboratory evidence of immunoglobulin A deficiency.&#xD;
&#xD;
          -  A history of previous administration of rabies vaccine or HRIG.&#xD;
&#xD;
          -  History of live virus vaccine administration, e.g., measles vaccine, within the last 3&#xD;
             months.&#xD;
&#xD;
          -  History of anaphylactic or anaphylactoid hypersensitivity reactions to chicken egg;&#xD;
             history of mild allergic reactions to chicken egg, e.g., skin rash only, is not an&#xD;
             exclusion criterion&#xD;
&#xD;
          -  History of hypersensitivity reaction to any of the following components of active&#xD;
             rabies vaccine (US-FDA approved) e.g.: neomycin, bovine gelatin, trace amounts of&#xD;
             chicken protein, chlortetracycline, and amphotericin B and in accordance with the&#xD;
             product insert of the vaccine.&#xD;
&#xD;
          -  History of hypersensitivity reaction to any of the components in an equivalent active&#xD;
             Rabies vaccine.&#xD;
&#xD;
          -  History of allergy to blood or blood products.&#xD;
&#xD;
          -  History of bleeding disorders.&#xD;
&#xD;
          -  Fever at the time of the start of the infusion. (Oral temperature &gt;38ºC.)&#xD;
&#xD;
          -  Clinically significant intercurrent illnesses including: cardiac, hepatic, renal,&#xD;
             endocrine, neurological, hematological, neoplastic, immunological, skeletal or other)&#xD;
             that in the opinion of the investigator, could interfere with the safety, compliance&#xD;
             or other aspects of this study.&#xD;
&#xD;
          -  Evidence of active systemic infection that required treatment with antibiotics within&#xD;
             2 weeks of the time of drug administration.&#xD;
&#xD;
          -  Evidence of uncontrolled hypertension (systolic blood pressure of &gt;150 mm Hg, and/or&#xD;
             diastolic blood pressure of &gt;100 mm Hg).&#xD;
&#xD;
          -  Heart rate &gt;120/min.&#xD;
&#xD;
          -  Weight &gt; 93.75 kg&#xD;
&#xD;
          -  Pregnancy and/or lactation.&#xD;
&#xD;
          -  Woman of child-bearing potential not taking adequate contraception deemed reliable by&#xD;
             the investigator.&#xD;
&#xD;
          -  All types of malignancies except for basal and squamous cell (scaly or plate-like)&#xD;
             skin cancer or situ cervical carcinoma must be in remission for a minimum of 5 years.,&#xD;
             For non-melanoma skin cancers and carcinoma in-situ of the cervix may be enrolled if&#xD;
             treated and cured at the time of screening.&#xD;
&#xD;
          -  Previous organ transplant recipient.&#xD;
&#xD;
          -  Evidence of ongoing infection with Hepatitis A, C, or B, or HIV 1/2.&#xD;
&#xD;
          -  Presence of psychiatric disorder, other mental disorder or any other medical disorder&#xD;
             which might impair the subject's ability to give informed consent or to comply with&#xD;
             the requirements of the study protocol.&#xD;
&#xD;
          -  Previous enrolment in this study.&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days prior to baseline visit.&#xD;
&#xD;
          -  Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally&#xD;
             prescribed drugs in the past 10 years.&#xD;
&#xD;
          -  History of life threatening allergy, anaphylactic reaction, or systemic response to&#xD;
             human plasma derived products.&#xD;
&#xD;
          -  Known hypersensitivity to any of the ingredients or excipients of the study drugs.&#xD;
&#xD;
          -  Any other factor that, in the opinion of the investigator, would prevent the subject&#xD;
             from complying with the requirements of the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Matson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prism Research Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prism Research Inc</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>November 28, 2013</study_first_submitted>
  <study_first_submitted_qc>January 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <results_first_submitted>June 8, 2016</results_first_submitted>
  <results_first_submitted_qc>August 31, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 29, 2021</results_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>KamRAB</title>
          <description>KamRAB 20 IU/kg body weight via IM injection, once on Day 0&#xD;
Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28</description>
        </group>
        <group group_id="P2">
          <title>FDA Approved Commercially Available HRIG Product</title>
          <description>Comparator product: IM injection once on Day 0 in the same manner and at the same dosage as KamRAB.&#xD;
Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>KamRAB</title>
          <description>KamRAB 20 IU/kg body weight via IM injection, once on Day 0&#xD;
Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28</description>
        </group>
        <group group_id="B2">
          <title>HRIG Comparator Product</title>
          <description>FDA Approved Commercially Available HRIG Product: IM injection once on Day 0 in the same manner and at the same dosage as KamRAB.&#xD;
Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="118"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.3" spread="16.15"/>
                    <measurement group_id="B2" value="46.3" spread="14.5"/>
                    <measurement group_id="B3" value="44.8" spread="15.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Difference Between KamRAB and HRIG Comparator, in the Proportions of Subjects With Serum Anti-rabies IgG Antibody Concentration ≥ 0.5 IU/mL</title>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>KamRAB</title>
            <description>KamRAB 20 IU/kg body weight via IM injection, once on Day 0&#xD;
Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28</description>
          </group>
          <group group_id="O2">
            <title>HRIG Comparator Product</title>
            <description>FDA Approved Commercially Available HRIG Product: IM injection once on Day 0 in the same manner and at the same dosage as KamRAB.&#xD;
Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28</description>
          </group>
        </group_list>
        <measure>
          <title>The Difference Between KamRAB and HRIG Comparator, in the Proportions of Subjects With Serum Anti-rabies IgG Antibody Concentration ≥ 0.5 IU/mL</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that Cp ≤ -0.1.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>We will reject the null hypothesis at the one-sided 5% significance level, and conclude that Cp &gt; -0.1, if the lower bound of an exact 90% binomial confidence interval (CI) exceeds0.1. A sample size of 53 in each group provides 80% power to reject the null hypothesis.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.018</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.082</ci_lower_limit>
            <ci_upper_limit>0.031</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signature of informed consent (ICF) to 185 days (post 8 half lives of product)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>KamRAB</title>
          <description>KamRAB 20 IU/kg body weight via IM injection, once on Day 0&#xD;
Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28</description>
        </group>
        <group group_id="E2">
          <title>FDA Approved Commercially Available HRIG Product</title>
          <description>Comparator product: IM injection once on Day 0 in the same manner and at the same dosage as KamRAB.&#xD;
Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <description>Intraductal proliferative breast lesion that was &quot;moderate&quot; in intensity, considered &quot;not related&quot; to study drug by the Principal Investigator, and was ongoing at the end of the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA Version 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="59" subjects_affected="29" subjects_at_risk="59"/>
                <counts group_id="E2" events="43" subjects_affected="43" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>agreement disclosure that restricts the right of the PI to discuss or publish trial results after the trial is completed</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eran Schenker, VP Medical Director</name_or_title>
      <organization>Kamada</organization>
      <phone>+972-8-9406472</phone>
      <email>Erans@kamada.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

